Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22,710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Among authors: lee sh, lee t, lee m, lee jy, lee jk. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
Multivariate analysis of prognostic factors in patients with pulmonary actinomycosis.
Park JY, Lee T, Lee H, Lim HJ, Lee J, Park JS, Cho YJ, Park YS, Lee CH, Lee SM, Yoon HI, Yim JJ, Yoo CG, Kim YW, Han SK, Lee CT, Lee JH. Park JY, et al. Among authors: lee ch, lee t, lee h, lee j, lee sm, lee jh, lee ct. BMC Infect Dis. 2014 Jan 9;14:10. doi: 10.1186/1471-2334-14-10. BMC Infect Dis. 2014. PMID: 24400792 Free PMC article.
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ. Lee M, et al. Among authors: lee sh, lee t, lee jy, lee jh. Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1. Trials. 2019. PMID: 30651149 Free PMC article.
A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study.
Park SY, Kim S, Kim JH, Kim SH, Lee T, Yoon SY, Kim MH, Moon JY, Yang MS, Jung JW, Kim JH, Choi JH, Park CS, Kim S, Lee J, Kwon JW, Hur GY, Kim SH, Kim HK, Shin YS, Kim SH, Nam YH, Jang AS, Park SY, Kim TB; Cohort for Reality and Evolution of Adult Asthma in Korea (COREA) Study Group. Park SY, et al. Among authors: lee t, lee j. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1304-1311.e2. doi: 10.1016/j.jaip.2020.09.066. Epub 2020 Nov 9. J Allergy Clin Immunol Pract. 2021. PMID: 33184024 Clinical Trial.
22,710 results
You have reached the last available page of results. Please see the User Guide for more information.